MannKind

MannKind Corporation (Nasdaq: MNKD) is dedicated to the development, development, and commercialization of therapeutic products for patients with diseases such as diabetes. Its primary candidate product, AFREZZA (R), is currently undergoing late-stage clinical research for the treatment of adults with type 1 or type 2 diabetes to control hyperglycemia.